Loading resource…

American College of Cardiology Foundation
The review highlights the prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD) in patients with cardiovascular, kidney, and metabolic (CKM) disorders. It discusses the shared pathophysiological mechanisms and the implications for clinical outcomes when these conditions coexist. The authors critique existing clinical trials that often focus on single disease states, leading to knowledge gaps, and propose a framework for designing multiorgan trials that incorporate diverse endpoints and patient-centered approaches.
No account needed